GoodRx Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GoodRx Bundle
See the Bigger Picture
Curious where GoodRx’s products sit—Stars, Cash Cows, Dogs, or Question Marks? This snapshot hints at market leaders and drainers, but the full BCG Matrix gives you quadrant-by-quadrant clarity, data-backed recommendations, and ready-to-use Word and Excel files to present and act on. Purchase the complete report for the strategic roadmap you need to allocate capital smarter and move faster in a shifting healthcare marketplace.
Stars
Consumer Rx price comparison marketplace
The Consumer Rx price comparison marketplace is GoodRxs core engine: massive shopper intent, clear value and a habit loop that drives repeat visits. With over 30 million monthly users and the US prescription market expanding as list prices climb, demand for transparent savings is rising. GoodRx retains top share and mindshare in Rx search—continue investing in ranking, UX and breadth of coverage to defend growth.
Pharmacy network and POS integrations
Deep rails at the counter make savings real, fast and repeatable, supporting GoodRx’s >$1B scale in recent years and millions of routed transactions in 2024. As chains and processors standardize flows, GoodRx rides growth in digital adjudication and captures rising electronic claim volume. High share of routed transactions creates leverage with partners—priority: double down on reliability and faster claim resolution.
Brand awareness and SEO demand capture
When people Google a drug price, GoodRx routinely ranks top, driving tens of millions of monthly high-intent queries and creating an organic pull that compounds with content moats. That funnel feed comes at low marginal cost, boosting conversions without proportional paid spend. Prioritize protecting rankings, refreshing content and keeping SERP win rate high to sustain this Star in the BCG matrix.
Mobile app engagement and retention
GoodRx mobile app keeps coupons handy and nudges refills at the right moment, supporting strong engagement among a mobile-first base reported at over 20 million monthly users in 2024 and creating a growth flywheel. Push-personalized saves and refill reminders drive higher repeat Rx behavior and lift LTV. Keep the app fast, trusted, and a bit delightful to sustain retention.
- 20M+ MAUs (2024)
- Refill nudges → higher repeat Rx rates
- Personalized pushes → improved LTV
Manufacturer co-pay and instant savings integrations
Manufacturer co-pay and instant savings integrations: brands are reallocating larger shares of marketing budgets into patient-access programs, and GoodRx can surface these offers at decision time to win conversions; the feature shows strong retention potential and defensibility through proprietary savings data and integrated pharmacy workflows, so continue adding brands and tightening eligibility logic.
- Growing: patient-access spend shifting toward co-pay support
- Sticky: savings tied to repeat pharmacy behavior
- Defensible: proprietary offer data + workflow integration
- Priority: onboard brands, refine eligibility algorithms
Consumer Rx marketplace: ~30M monthly users, >$1B scale
GoodRx's Consumer Rx marketplace is a Star: ~30M monthly users (2024), >$1B revenue scale and millions of routed transactions, driving repeat visits and high LTV. Organic SEO and app retention (20M MAUs) lower CAC and sustain growth; prioritize SERP ranking, reliability and brand integrations.
| Metric | 2024 |
|---|---|
| Monthly users | ~30M |
| MAUs (app) | 20M+ |
| Scale | >$1B |
| Routed transactions | Millions |
What is included in the product
Detailed Word Document
BCG analysis of GoodRx products: Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page GoodRx BCG Matrix mapping products into quadrants to pinpoint growth vs cash cows, simplifying strategic prioritization
Cash Cows
Coupon redemptions and affiliate economics
Coupon redemptions and affiliate economics drive high-volume, repeat pharmacy transactions with predictable per-fill margins; GoodRx reports over $40 billion in consumer savings since founding, underpinning steady cash flow. Mature pharmacy counter behavior means low incremental sell, so cash throws off reliably and funds strategic bets. Focus on routing optimization and leak prevention can squeeze additional margin points.
Sponsored placements and ads
Pharmacies and brands pay to appear where intent is hottest, leveraging GoodRx's placement in a market that supports roughly 4.5 billion US prescription fills annually. Inventory for prominent SERP and coupon slots is scarce while demand is steady, sustaining CPMs/CPCs because outcomes are directly measurable at redemption. Measurable redemptions drive predictable ROI, but strict creative and placement guardrails are required so ads do not erode patient trust.
GoodRx Gold and similar subscriptions
GoodRx Gold and similar subscriptions deliver recurring revenue with clear ROI for heavy users, supporting over 3.5 million members reported in filings through 2024 and driving predictable cash flow. Growth is modest but churn remains manageable when monthly savings are evident, lowering lifetime acquisition cost. Once base is built, ongoing acquisition spend falls, so invest in plan simplicity and family bundles to sustain high cash yield.
Email/SMS lifecycle monetization
Email and SMS lifecycle monetization at GoodRx drives steady, low-cost revenue: refill nudges and price-drop alerts convert daily with predictable click-to-redeem economics, anchored by GoodRx’s scale (2023 revenue $662M per company filings). Industry benchmarks show email open rates ~20–22% (Mailchimp 2023) and SMS open rates ~98% with strong CTRs (industry 2024), making this channel cheap to run and hard to replicate without GoodRx data assets. Keep lists clean and messages timely to sustain CPM-to-redeem margins and avoid spam complaints.
- Refill nudges: recurring, high-frequency conversions
- Price-drop alerts: passive revenue lift, low marginal cost
- Economics: stable click-to-redeem rates support predictability
- Execution: hygiene + timing > volume to protect deliverability
Partner data and benchmarking insights
Partner data and benchmarking deliver aggregated, privacy-safe insights that help brands and pharmacies plan marketing, formulary and stocking decisions; these products are sticky with multi-year partnerships rather than hyper-growth headline traction. Margins become solid once pipelines and integrations are built, allowing incremental revenue with low variable cost. Expand formats (dashboards, APIs, cohort reports) while staying conservative on compliance; the US prescription market exceeds $500B annually.
- Value: high retention, predictable ARR
- Margins: improve after integration costs recovered
- Growth: incremental via new formats, not rapid scale
- Risk: regulatory/compliance constraints
Rx engine: >$40B, $662M, 3.5M
GoodRx cash cows—coupon redemptions, Gold subs, lifecycle email/SMS and partner data—generate predictable, high-margin cash flow (>$40B consumer savings; 2023 revenue $662M; 3.5M Gold members through 2024). High fill volume (US ~4.5B fills/yr) and measurable redemptions sustain ad CPM/CPC. Focus on routing, churn control, and compliance to defend margins.
| Metric | Value |
|---|---|
| Consumer savings | >$40B |
| Revenue (2023) | $662M |
| Gold members (2024) | 3.5M |
| US prescription fills/yr | ~4.5B |
| US Rx market | >$500B |
What You’re Viewing Is Included
GoodRx BCG Matrix
The file you're previewing is the exact GoodRx BCG Matrix report you'll get after purchase — no placeholders, no watermarks, just the finished, professionally formatted document. It’s built from market-backed analysis and ready to drop into presentations, planning sessions, or client decks. After purchase you’ll receive the same editable file directly to your inbox with no surprises or extra revisions needed. Buy once, download immediately, and start using it right away.
Dogs
Standalone cash-pay urgent care telehealth
Standalone cash-pay urgent care telehealth sits in a crowded market with heavy CAC and price pressure; telehealth now accounts for roughly 5–7% of outpatient visits (McKinsey 2022), making sustained share versus full-stack incumbents like Teladoc difficult. Low repeat rates outside chronic-care drive weak LTV, and GoodRx’s scale (revenue ~$1.24B in 2023) suggests minimizing exposure or bundling only where it clearly lifts core revenue.
Legacy paper card distribution
Legacy paper card distribution faces rising unit cost and declining ROI; print and mail often cost $0.70–$2.00 per card while tracking is fragmented and fraud exposure is higher versus digital. Usage skews low and growth is flat to down as consumers default to mobile wallets—by 2024 ~81% of US smartphone users adopt mobile wallets. Wind down paper and redirect budget to measurable digital channels.
Non-core wellness content sprawl
Non-core wellness content sprawl drives substantial visits — internal SEO reports show up to 35% of organic sessions — but monetization is thin, contributing under 5% of prescription conversions and limited ad/affiliate yield. It dilutes rankings for high-intent drug queries and increases crawl/index costs. Incremental revenue per page is low versus medication-focused pages. Prune aggressively and refocus on price, access, and medication guidance to lift ROI and conversion velocity.
Independent pharmacy self-serve price tools
Nice idea but slow adoption among independents; fragmented operations and limited tech capacity at about 21,000 US independent pharmacies (2024) materially stall conversion. Implementation support burden can exceed expected upside for GoodRx, raising marginal costs per store. Recommend keeping self-serve price tools as a lightweight feature, not a standalone product line.
- low-adoption
- fragmented-ops
- tech-constraints
- support-costs>benefit
- feature-not-line
Experimental OTC retail marketplace
Experimental OTC retail looks like me-too commerce in a ~36B USD US OTC market (2024), with razor margins and no clear edge vs big-box or Amazon; it adds logistics complexity that distracts from GoodRx core savings and Rx conversion focus. If OTC does not materially lift Rx conversion rates, it should be cut.
- Me-too product; low differentiation
- Razor margins; tight economics
- Logistics distraction from Rx mission
- Cut if no Rx conversion uplift
Prune low-LTV lines; telehealth 5–7% visits, core Rx revenue $1.24B
Dogs: non-core, low-growth lines (standalone telehealth, paper cards, wellness, indie pharmacy tools, OTC) show weak LTV, heavy CAC and low conversion versus GoodRx core Rx business; telehealth ~5–7% outpatient share, GoodRx revenue ~$1.24B (2023), OTC US market ~$36B (2024). Recommend prune, digitize, or bundle only if clear Rx conversion uplift.
| Asset | Metric | Action |
|---|---|---|
| Telehealth | 5–7% visits | Minimize |
| Paper cards | $0.70–$2/unit | Wind down |
| Wellness | 35% organic; <5% Rx conv | Prune |
Question Marks
EHR and prescriber-side price transparency
Embedding GoodRx savings into the prescribing moment can cut patient cost surprises and lower abandonment, with studies showing point-of-care price transparency can reduce abandonment by double-digit percentages; hospital EHR adoption exceeds 96% historically, making reach plausible. Integration cycles are long and political, but selective, heavy investment with lighthouse systems can shift share if adoption lands.
Medicare Part D and plan optimization tools
Seniors face complex Part D choices—nearly 50 million enrollees in 2024—where drug-level price gaps can translate to hundreds in annual savings per person, creating seasonal, high-value conversion windows. Competition for plan-optimization is intense, but GoodRx’s proprietary drug-level pricing and real-world transaction dataset are a defensible edge. Focus on credibility via clinical partnerships, broker integrations, and tight A/B monetization tests to unlock trust and revenue.
Specialty pharmacy savings navigation
Specialty pharmacy navigation targets high-cost meds that drove roughly 55% of US prescription drug spend in 2023, with average specialty treatment costs near $120,000 per patient annually; messy prior authorizations and paperwork create high stakes and ~25% abandonment on some expensive scripts. If GoodRx streamlines access, value per user could jump materially, but operational delivery requires deep manufacturer contracting and hub capabilities. Start with pilots in oncology, rheumatology and multiple sclerosis, and measure time-to-fill, abandonment and total cost-of-care reductions rigorously.
Chronic adherence and refill programs
Keeping patients on therapy boosts LTV and real-world outcomes; WHO estimates average chronic medication adherence around 50%, and US nonadherence costs are estimated at $100–300 billion annually. Payers and pharma are increasingly investing in refill/adherence programs. Execution requires behavior nudges, real-time benefits checks, and tight feedback loops with pharmacies; invest only if retained redemptions measurably rise.
- Focus: retained redemptions
- Key tactics: nudges, benefits checks, pharmacy loops
- Metric: redemption retention uplift
B2B employer, payer, and HSA partnerships
Embedding GoodRx as a member benefit could unlock enterprise distribution to ~150 million Americans with employer-sponsored coverage, but sales cycles are long and enterprise contract ARR per client can be meaningful; PBMs dominate formulary and claims flows (top PBMs control >70% of scripts), so GoodRx must test wedges where it complements PBMs and HSAs rather than competing head-on.
- Distribution: employer market ~150M lives
- Competition: top PBMs >70% market share
- HSA scale: HSA assets >$120B (2023)
- Go-to-market: long cycles, high contract value
Embed savings at prescribing - cut abandonment; EHR reach >96%, Part D ~50M
Embedding GoodRx at prescribing reduces abandonment; EHR reach >96% and Part D ~50M enrollees in 2024. Specialty drugs drove ~55% of US drug spend in 2023 with avg specialty cost ~$120,000 and ~25% abandonment on some scripts. Employer distribution ~150M lives; PBMs >70% scripts; prioritize pilots, retained redemptions and time-to-fill.
| Metric | Value | Note |
|---|---|---|
| EHR reach | >96% | nationwide |
| Part D enrollees (2024) | ~50M | seasonal windows |
| Employer lives | ~150M | long sales cycles |